Benjamin Besse, MD, PhD, discusses the biomarker analysis of the phase 1/1b CHRYSALIS-2 study of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.
Benjamin Besse, MD, PhD
Advertisement
Benjamin Besse, MD, PhD, is a medical oncologist specializing in the management of thoracic cancers and director of clinical research at Gustave Roussy Cancer Campus Grand Paris.
Articles by Benjamin Besse, MD, PhD
Benjamin Besse, MD, PhD, discusses the main findings and next steps of the phase 1/1b CHRYSALIS-2 study in EGFR-mutated non–small cell lung cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
